BioMarin Pharmaceutical, Inc. (BMRN)
$16.35
-0.10 (-0.64%)
| CAPS Rating |
|
|---|---|
| Open | $16.84 |
| Previous Close | $16.46 |
| Daily Range | $16.13 - $16.84 |
| 52-Week Range | $9.93 - $21.23 |
| Market Cap | $1.65B |
| P/E Ratio | 36.89 |
| Dividend (Yield) | N/A (N/A) |
| Volume | 539,460 |
| Average Daily Volume | 1,308,000 |
How do you think BMRN will perform vs the S&P 500?
Caps
Motley Fool CAPS is a community working together to find better stocks and to become better investors.
BMRN Advanced Details
- CAPS Community Analysis: Commentary, Scorecard
- Advanced Financial Analysis: Historical Prices, Chart, Stats, Ratios, Earnings/Growth Rates, Statements, SEC Filings
BMRN News and Commentary
- UPDATE 1-BioMarin autoimmune disease drug gets orphan status – Reuters
- The Next Million-Dollar Penny Stock – The Motley Fool
- CNBC on BioMarin Pharmaceuticals Inc – Ockham-RazorWire
- Finally Convinced? Benlysta Works! – The Motley Fool
- Earnings? Yawn. Trial Data? Moving! – The Motley Fool
- This Week's 5 Smartest Stock Moves – The Motley Fool
- Small and Volatile, but Not for Long – The Motley Fool
- Small Market, Small Acquisition, Still a Good Move – The Motley Fool
- Build Your Fortune With These Winners – The Motley Fool
- The Next Million-Dollar Penny Stock – The Motley Fool
- Biomarin (BMRN) possible buyout – Blog at The Motley Fool
- Is There Life After a 714% Return? – The Motley Fool
- 7 Stocks With a Bright Future – The Motley Fool
- The Cash Cow Is Out of Milk – The Motley Fool
- The Little Orphan That Could – The Motley Fool
- Overnight Triple! Yee-Haw! – The Motley Fool
- A Meaningless FDA Approval ... for Now – The Motley Fool
- Going Viral, but Not in a Good Way – The Motley Fool
- Where Good Drugs Go to Die – The Motley Fool
- 4-Star Stocks Poised to Pop: BioMarin – The Motley Fool


RSS Headlines
Fool UK